Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial.
about
The emerging role of biotechnological drugs in the treatment of goutAn old disease with new insights: Update on diagnosis and treatment of gout.Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: premises, perils, and perspectivesAdipokines as drug targets in diabetes and underlying disturbances.Targeting the inflammasome in rheumatic diseases.Treating inflammation by blocking interleukin-1 in humans.Gout in 2013. Imaging, genetics and therapy: gout research continues apace.Anti-interleukin-1 therapy in the management of gout.Canakinumab for gout: a specific, patient-profiled indication.Febuxostat: drug review and update.Prophylaxis for acute gout flares after initiation of urate-lowering therapy.Advances in pharmacotherapy for the treatment of gout.Chimeric fusion proteins used for therapy: indications, mechanisms, and safety.Canakinumab for the treatment of familial Mediterranean fever.Interleukin-1 Blockade: An Update on Emerging Indications.Hyperuricemia in Tendons.Hyperuricemia and gout in solid-organ transplant: update in pharmacological management.Feasibility randomised multicentre, double-blind, double-dummy controlled trial of anakinra, an interleukin-1 receptor antagonist versus intramuscular methylprednisolone for acute gout attacks in patients with chronic kidney disease (ASGARD): protocRecent pharmacological advances in the management of gout.The British Society for Rheumatology Guideline for the Management of Gout.Langfassung zur S2e-Leitlinie Gichtarthritis (fachärztlich)NLRP3 inflammasome inhibitor OLT1177 suppresses joint inflammation in murine models of acute arthritis
P2860
Q26825459-4E40E2E1-99FE-42D4-AD0C-1981DAF8C04CQ34542091-419A0C11-5B87-4EF7-AEC8-3AB3F76ADD39Q35133812-210E1584-9894-42B9-B126-44F45B118BA9Q35415815-9E64538F-2D60-47D5-813D-B501710D3114Q35804717-23890F93-D081-4D84-8515-DCCC65A97C38Q37636664-51F899CA-E4C4-4E5F-9F9A-B31D8DDC2B9CQ38166203-0BEFF16A-7A7F-4287-932E-7C95892F5C26Q38177186-BD8D41E4-5EC5-40A7-832C-15D088CA9C23Q38180827-4CD88C92-BC27-4FAA-B4BA-B42910E92165Q38200657-2DF05F00-345C-4640-BD98-9998F87E6C0CQ38206603-95F2D030-B9E7-4D22-95BF-7F11B8D3ECDBQ38303416-EBDE813B-BF40-482F-BDC4-4B205565A643Q38400396-8A707709-B9F9-4649-8EAC-C41BD1262504Q38865019-A88A5FBD-B9CA-4BCA-9BB0-FB6D5C76FAA7Q39301613-9AA8DC33-7882-4D1D-85DC-0E4610FC2209Q39480194-F1F843FC-88B8-499B-941C-173E2CAD0641Q40605885-CC8A4EFB-8F60-430B-83F8-80EF50E72CF4Q41581182-41A4F289-C339-45A4-BE94-F997A26C3086Q47919692-73D0AA36-773D-41AF-9EAC-861E8054F38EQ55060116-B563FDF1-D106-47C7-BB4D-498E181BB2C4Q56637250-F27CEB38-ED0B-40C7-8951-1B7BD9C536DAQ58801340-88277E03-0C0D-47AE-8801-513C312D3B4A
P2860
Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Rilonacept for gout flare prev ...... zed, placebo-controlled trial.
@en
Rilonacept for gout flare prev ...... zed, placebo-controlled trial.
@nl
type
label
Rilonacept for gout flare prev ...... zed, placebo-controlled trial.
@en
Rilonacept for gout flare prev ...... zed, placebo-controlled trial.
@nl
prefLabel
Rilonacept for gout flare prev ...... zed, placebo-controlled trial.
@en
Rilonacept for gout flare prev ...... zed, placebo-controlled trial.
@nl
P2093
P2860
P356
P1433
P1476
Rilonacept for gout flare prev ...... zed, placebo-controlled trial.
@en
P2093
Essack Mitha
George D Yancopoulos
H Ralph Schumacher
Leon Fouche
Robert R Evans
Shirletta King-Davis
Shue-Fen Luo
Steven P Weinstein
P2860
P304
P356
10.1093/RHEUMATOLOGY/KET114
P577
2013-03-13T00:00:00Z